Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Filings indexed 336 across all filing types
Latest filing 2024-01-08 Director's Dealing
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2024-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Jung Sung-hoon) of Celltrion Pharm. This type of filing, which details personal share transactions or changes in ownership status by company insiders, is classified as 'Director's Dealing' (DIRS) in the provided schema.
2024-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose their shareholdings and changes therein. This corresponds to the 'Director's Dealing' category, which covers insider trades and ownership reports by company directors and executives.
2024-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 4.1' report) used to disclose insider shareholdings and changes in ownership by company directors or major shareholders. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers insider trades and ownership reports by executives.
2024-01-08 Korean
배당락(주식배당)
Notice of Dividend Amount Classification · 100% confidence The document is a short notice regarding '배당락' (ex-dividend date) for Celltrion Pharm. It specifies the ex-dividend date, the reference price, and the reason (stock dividend). Since it is a specific announcement regarding dividend mechanics rather than the declaration of the dividend amount itself or a full financial report, it falls under the category of regulatory announcements.
2023-12-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Choi Seung-jae) of Celltrion Pharm. This type of filing, which details personal share transactions by company insiders, is classified as 'Director's Dealing' (DIRS) in the provided taxonomy.
2023-12-22 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.